<?xml version="1.0" encoding="UTF-8"?>
<document id="28147318">
	<sentence id="s1" text="KRT5 and KRT6 (KRT6A, KRT6B AAAAA KRT6C) gene expression was assessed in publically available serous ovarian cancer data sets, ovarian cancer cell lines and primary serous ovarian cancer cells.">
		<entity id="s1.e1" charOffset="0-4"
			type="GENE" text="KRT5" ontology_id="3852"/>
		<entity id="s1.e2" charOffset="9-13"
			type="GENE" text="KRT6" ontology_id="140807"/>
		<entity id="s1.e3" charOffset="109-115"
			type="HP" text="cancer" ontology_id="HP_0002664"/>
		<pair id="s1.p1" e1="s1.e3"
		    e2="s1.e3" pgr="false"/>
		<pair id="s1.p2" e1="s1.e1"
		    e2="s1.e3" pgr="true"/>
	</sentence>
	<sentence id="s2" text="Survival analyses showed that high KRT5 mRNA in stage III/IV serous ovarian cancers was significantly associated with reduced progression-free (HR 1.38, P AAAA 0.0001) and overall survival (HR 1.28, P = 0.013) whilst high KRT6 mRNA was only associated with reduced progression-free survival (HR 1.2, P = 0.031).">
		<entity id="s2.e1" charOffset="35-39"
			type="GENE" text="KRT5" ontology_id="3852"/>
		<entity id="s2.e2" charOffset="76-82"
			type="HP" text="cancer" ontology_id="HP_0002664"/>
		<entity id="s2.e3" charOffset="222-226"
			type="GENE" text="KRT6" ontology_id="140807"/>
		<pair id="s2.p1" e1="s2.e3"
		    e2="s2.e3" pgr="false"/>
		<pair id="s2.p2" e1="s2.e1"
		    e2="s2.e2" pgr="true"/>
	</sentence>
	<sentence id="s3" text="KRT5 but not KRT6C mRNA expression was increased in chemotherapy resistant primary serous ovarian cancer cells compared to chemotherapy sensitive cells.">
		<entity id="s3.e1" charOffset="0-4"
			type="GENE" text="KRT5" ontology_id="3852"/>
		<entity id="s3.e2" charOffset="13-17"
			type="GENE" text="KRT6" ontology_id="140807"/>
		<entity id="s3.e3" charOffset="98-104"
			type="HP" text="cancer" ontology_id="HP_0002664"/>
		<pair id="s3.p1" e1="s3.e3"
		    e2="s3.e3" pgr="false"/>
		<pair id="s3.p2" e1="s3.e1"
		    e2="s3.e3" pgr="true"/>
	</sentence>
</document>
